SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is facing a critical crossroads following FDA briefing documents that sharply questioned the company's clinical trial data, leading to a significant sell-off as investors brace for the upcoming advisory committee meeting. The community is intensely debating whether the drug's clinical benefit and high unmet need can overcome the regulatory body's concerns regarding data integrity and trial design, with many closely watching for signs of another Complete Response Letter.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trending as investors debate whether the stock is a deep-value opportunity after its significant pullback or a long-term turnaround play struggling with brand relevance and China distribution hurdles. The community remains sharply divided, with some actively accumulating shares near current lows while others caution that the athletic giant faces structural headwinds and stiff competition that could keep the stock suppressed.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as investors weigh strong Q1 cash generation and volume growth against the heightened uncertainty of today's Supreme Court oral arguments regarding patent litigation. The community remains deeply divided between long-term holders banking on proprietary formulation catalysts and skeptics frustrated by years of stagnant stock performance and legal setbacks.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit Inc is experiencing significant market volatility after investors reacted negatively to commentary regarding choppy search-driven traffic, despite the company reporting a strong revenue beat and raised guidance. The community is actively debating the durability of its AI licensing deals and user growth metrics, while traders are clashing over whether the current double-digit selloff represents a major liquidity flush and buying opportunity or a deeper fundamental issue.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is currently under intense scrutiny as community members debate Cathie Wood's conviction-based strategy, with some criticizing the fund's long-term performance compared to broader benchmarks while others view the current price action as a structural accumulation phase. Sentiment remains polarized between those calling for an exit due to persistent drawdowns and those monitoring the fund's active rotation into and out of high-growth tech, AI, and crypto-related equities.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following positive institutional developments, including a recent record-breaking auto ABS deal and significant insider purchasing from the CEO, which have bolstered investor confidence. The community is actively discussing a potential re-rating of the stock as it shows resilience despite broader fintech volatility, with many participants pointing to strong quarterly fundamentals and ongoing analyst upgrades as catalysts for future growth.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is currently a key focus for the market as it navigates a record production backlog and recently secured multi-billion dollar government contracts to bolster missile and defense system inventories. Investors are actively debating the stock's potential for long-term growth driven by sustained geopolitical tensions and the company's critical role in replenishing depleted U.S. and allied munitions stockpiles.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar Automotive Holding UK PLC

Polestar is facing heightened volatility and bearish sentiment amid concerns over a potential delisting, weakening sales, and an ongoing cash burn that has left many investors questioning the company's long-term viability. While management is attempting to pivot strategy with a new model offensive and attempts to secure financial footing, the community remains deeply divided, with many retail investors expressing frustration over significant losses and the stock's performance compared to broader market trends.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors weigh strong Farnborough Airshow order volume against ongoing operational challenges, including persistent cost overruns on the Air Force One program. While the community remains divided over the company's ability to turn its massive backlog into consistent free cash flow, many are closely monitoring the stock's performance ahead of upcoming earnings as a pivotal test for the new CEO's turnaround strategy.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is experiencing high volatility and massive trading volume as the community debates whether the activity signals institutional accumulation or ongoing market manipulation. Investors are fixated on the stock's significant short interest and strategic pivot toward agentic AI, monitoring for a potential breakout that could trigger a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down

ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026 revenue view.

Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alkermes (ALKS) Reports Break-Even Earnings for Q2

Alkermes (ALKS) delivered earnings and revenue surprises of +100.00% and +9.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alkermes plc Reports Second Quarter 2026 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the companys investor relations website at https://investor.alkermes.com. Alkermes will host a conference...

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance

AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.

Alkermes to Report Second Quarter Financial Results on July 28, 2026

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the companys second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes...

Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study

Alkermes reports positive long-term data for alixorexton, showing sustained wakefulness and symptom improvements in NT1 and NT2 narcolepsy.read more...

Alkermes Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

Alkermes plc (Nasdaq: ALKS) today announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Across all dose groups in both NT1 and NT2 participants, alixorexton...

$ALKS Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.00
• Reported revenue of $496.01M up 26.97% YoY
• Alkermes plc updated its 2026 expectations, now projecting a GAAP net loss of $95 million to $115 million and EBITDA of $75 million to $95 million, while maintaining other financial guidance.

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALKSAlkermes plc

Fundamentals

Connect Stocktwits to ChatGPT

Latest ALKS News